Paulo Guillinta, MD
Cardiovascular Disease · Chula Vista, CANPI 1881661536
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Abbott accounts for 82.1% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2023 at $12,162 and has fallen 89.2% since, to $1,318 in 2025. Among cardiovascular disease clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 190 payments — averaging $153.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$24K
- Edwards Lifesciences$1K
- Medtronic$910
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$525
- Siemens Medical Solutions USA, Inc.$490
- Philips North America LLC$473
- plus $1K from 12 others
Across 1 payment — averaging $1918.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$2K
What the payments were for
- Speaking & faculty fees$15,27552%
- Travel & lodging$5,37718%
- Food & beverage$8,50029%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 104 | $23,947 |
| Edwards Lifesciences | 14 | $1,327 |
| Medtronic(2 entities) | 7 | $910 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 29 | $525 |
| Siemens Medical Solutions USA, Inc. | 7 | $490 |
| Philips North America LLC | 6 | $473 |
| Abiomed | 2 | $263 |
| AstraZeneca | 4 | $259 |
| Amgen | 4 | $176 |
| Shockwave Medical, Inc | 1 | $152 |
| E.r. Squibb & Sons, L.L.C. | 2 | $138 |
| Cvrx, Inc. | 2 | $130 |
| Boehringer Ingelheim | 1 | $117 |
| Boston Scientific | 1 | $94 |
| Getinge USA Sales, LLC | 3 | $82 |
| Bard Peripheral Vascular, Inc. | 1 | $39 |
| Pfizer | 1 | $18 |
| Lantheus Medical Imaging, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MitraClip$7,330
- AMPLATZER TALISMAN$6,738
- MitraClip System$3,135
- Mitra Clip system$2,140
- SAPIEN 3 Ultra RESILIA$744
- Tendyne Mitral Valve System$622
- CoreValve Evolut$530
- (5044) MCOT$362
- ACUSON Origin Diagnostic Ultrasound System$288
- EVOQUE$255
- FARXIGA$233
- XIENCE SIERRA$183
- RESOLUTE ONYX$179
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$152
- TRICLIP$142
- Resolute$127
- Impella$126
- CAMZYOS$125
- Repatha$122
- Barostim Neo System$122
How this compares
$29,152 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 265 | $337,353 |
| VyndamaxTafamidis | 11 | $265,304 |
| JardianceEmpagliflozin | 180 | $230,782 |
| XareltoRivaroxaban | 149 | $165,848 |
| EntrestoSacubitril/Valsartan | 85 | $116,543 |
| FarxigaDapagliflozin Propanediol | 57 | $54,572 |
| Repatha SureclickEvolocumab | 40 | $41,492 |
| MultaqDronedarone Hcl | 19 | $28,616 |
| Repatha PushtronexEvolocumab | 22 | $27,419 |
| Praluent PenAlirocumab | 17 | $17,366 |
| Repatha SyringeEvolocumab | 17 | $14,022 |
| NexletolBempedoic Acid | 15 | $13,117 |
| Rosuvastatin Calcium | 275 | $7,812 |
| VascepaIcosapent Ethyl | 16 | $6,915 |
| Ranolazine ErRanolazine | 58 | $6,319 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Vyndamax | $18 | $602,657276 claims |
| Boehringer IngelheimJardiance | $117 | $230,782180 claims |
| AstraZenecaFarxiga | $259 | $54,57257 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Chula Vista
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
- Pam Taubla Jolla$1.2M
- Wilber SuStanford$1.1M
- Thomas SmithSacramento$942K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.